Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, December 2000, p. 3368-3373, Vol. 44, No. 12
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Characterization of an In Vitro-Selected
Amoxicillin-Resistant Strain of Helicobacter
pylori
Cindy R.
DeLoney and
Neal L.
Schiller*
Division of Biomedical Sciences, University of
California, Riverside, Riverside, California 92521
Received 31 January 2000/Returned for modification 25 April
2000/Accepted 5 September 2000
 |
ABSTRACT |
An amoxicillin-resistant (Amoxr) strain of
Helicobacter pylori was selected for by culturing an
amoxicillin-sensitive (Amoxs) strain in increasingly higher
concentrations of amoxicillin, resulting in a 133-fold increase in MIC,
from 0.03 to 0.06 µg/ml to 4 to 8 µg/ml. This resistance was stable
upon freezing for at least 6 months and conferred cross-resistance to
seven other
-lactam antibiotics.
-Lactamase activity was not
detected in this Amoxr strain; however, analysis of the
penicillin-binding protein (PBP) profiles generated from isolated
bacterial membranes of the Amoxs parental strain and the
Amoxr strain revealed a significant decrease in labeling of
PBP 1 by biotinylated amoxicillin (bio-Amox) in the Amoxr
strain. Comparative binding studies of PBP 1 for several
-lactams demonstrated that PBP 1 in the Amoxr strain had decreased
affinity for mezlocillin but not significantly decreased
affinity for penicillin G. In addition, PBP profiles prepared from
whole bacterial cells showed decreased labeling of PBP 1 and PBP 2 in
the Amoxr strain at all bio-Amox concentrations tested,
suggesting a diffusional barrier to bio-Amox or a possible antibiotic
efflux mechanism. Uptake analysis of 14C-labeled penicillin
G showed a significant decrease in uptake of the labeled antibiotic by
the Amoxr strain compared to the Amoxs strain,
which was not affected by pretreatment with carbonyl cyanide
m-chlorophenylhydrazone, eliminating the possibility of an
efflux mechanism in the resistant strain. These results demonstrate that alterations in PBP 1 and in the uptake of
-lactam antibiotics in H. pylori can be selected for by prolonged exposure to
amoxicillin, resulting in increased resistance to this antibiotic.
 |
INTRODUCTION |
Helicobacter pylori is
the most common cause of gastric and duodenal ulcers and is strongly
associated with the development of gastric adenocarcinoma (see
references 14 and 32 for reviews). It is estimated that at least a
third of the world's population is infected with H. pylori,
making it one of the most common infections in humans (14).
Successful treatment of H. pylori infections most often
employs the use of two or more antibiotics and the addition of either
bismuth or a proton pump inhibitor (14, 17, 18). However,
H. pylori resistance to many of the commonly used antibiotics in this triple regimen is rising (19), including resistance to metronidazole (1, 27, 36), clarithromycin (1, 6, 9, 27), rifampin or rifabutin (24), and,
recently, amoxicillin (11, 12, 13, 22, 38).
Resistance to
-lactam antibiotics by gram-negative bacteria is most
commonly due to the production of
-lactamase, either chromosomally encoded or, more often, plasmid mediated (see
reference 30 for a review). Other important mechanisms of resistance
include alterations in penicillin-binding proteins (PBPs),
decreased permeation of the antibiotic into the bacterial cell, or
combinations of these resistance strategies (see reference 28 for a
review). Active efflux pumps in gram-negative bacteria which excrete
drugs, including multidrug efflux pumps, can also confer resistance to
-lactams (see reference 34 for a review).
The PBPs are a set of enzymes involved in the synthesis of the
peptidoglycan layer of the bacterial cell wall and include transpeptidases, transglycosylases, endopeptidases, and
carboxypeptidases (4, 16). We have previously reported
the following molecular masses of four major PBPs in H. pylori ATCC 43579: 66, 63, 60 and 47 kDa (7). Other
investigators have also reported three to four PBPs for H. pylori (10, 26, 29). The molecular mass of a small PBP
was reported in the range of 30 to 32 kDa by both Dore et al.
(10) (named PBPD) and Krishnamurthy et al. (29) (named PBP4). Krishnamurthy et al. (29) also identified
three high-molecular-mass PBPs (PBPs 1, 2, and 3) from H. pylori 84-183 in the range of 66 to 55 kDa and indicated that
these PBPs corresponded to PBPs A, B, and C, previously
described by Ikeda et al. (26). Other PBPs in
H. pylori were recently identified by Harris et al. (23) at 72, 62, 54, 50, 44, 33.5, 30.5, and 28 kDa. For consistency with other PBP labeling systems, we shall therefore refer
to the three high-molecular-mass proteins identified in our laboratory
with apparent molecular masses of 66, 63, and 60 kDa as PBP 1, 2, and
3, respectively. However, we do not believe the PBP of 47 kDa we
identified corresponds to either PBP D or PBP 4 (30 to 32 kDa) and will
therefore continue to consider this protein from H. pylori
ATCC 43579 a putative PBP.
The covalent binding of
-lactam antibiotics to various PBPs results
in the inability of the bacterium to build a complete cell wall,
ultimately leading to cell lysis and death (15). Alterations
in these PBPs which affect the ability of the
-lactams to bind can
confer increased resistance of the bacteria to these antibiotics
(reviewed in references 21 and 31). Reports of alterations in PBPs
which result in resistance to
-lactams include PBPs 3a and 3b of
Haemophilus influenzae (35), PBP 1A of
Proteus mirabilis (33), PBPs 2b and 2x of
Streptococcus pneumoniae (20), and PBPs 1b, 2a,
and 2b of S. pneumoniae (25).
In this study we isolated an amoxicillin-resistant strain of
H. pylori and characterized the level of
antibiotic resistance in this strain, its stability, its
-lactam
cross-resistance, and the mechanism(s) responsible for its amoxicillin resistance.
 |
MATERIALS AND METHODS |
Bacterial culture conditions.
Stock cultures of H. pylori ATCC 43579 were streaked for isolation on brucella agar
(Becton-Dickinson Microbiology, Cockeysville, Md.) supplemented with
10% defibrinated sheep blood (Colorado Serum Company, Denver, Colo.)
and 1% IsoVitaleX (Becton-Dickinson Microbiology) and cultured at
37°C in a humidified 10% CO2 incubator. Liquid cultures
were prepared by suspension of H. pylori colonies in
brucella broth (Difco Laboratories, Detroit, Mich.) supplemented with
10% fetal bovine serum (Gibco Bethesda Research Laboratories, Grand
Island, N.Y.) and 1% IsoVitaleX. Cultures were routinely passed by
dilution into fresh media at 48-h intervals; however, in some
experiments, bacteria were passed into fresh media with increasing
concentrations of antibiotic at 72- to 96-h intervals. Freezer stocks
of cultures were prepared by resuspending 24-h cultures in 1% proteose
peptone-20% glycerol, flash frozen in liquid nitrogen, and kept at
80°C.
Development of amoxicillin resistance and MIC and MBC
determination.
Details for determination of the MIC using the
broth microdilution method and determination of the minimal
bactericidal concentration (MBC) of the
-lactam antibiotics were
published previously (7). Liquid cultures of
Amoxs H. pylori ATCC 43579 (MIC, 0.03 to 0.06 µg/ml) were passed by dilution into fresh media with increasing
concentrations of antibiotic at 3- to 4-day intervals in order to
select for amoxicillin resistance. These resulting
amoxicillin-resistant (Amoxr) bacteria (MIC, 4 to 8 µg/ml) were frozen and stored at
80°C. These Amoxr
isolates were also subcultured in broth media without antibiotic and
after freezing to determine the stability of amoxicillin resistance.
-Lactamase detection.
The production of
-lactamase by
these bacteria was tested by the chromogenic cephalosporin method using
nitrocefin BBL DrySlides as directed by the manufacturer
(Becton-Dickinson) using
-lactamase-positive Staphylococcus
aureus ATCC 27760 as a positive control.
Bio-Amox labeling of PBPs.
H. pylori membranes
were prepared as previously described (7) with the following
modifications. Membrane fractions were prepared from 4 liters of 48-h
cultures of Amoxs and Amoxr H. pylori and frozen at
20°C until analyzed. Biotinylated
amoxicillin (bio-Amox) was prepared by the method of Dargis and Malouin
(5) and kept frozen in aliquots at
80°C for up to 12 months. Membrane pellets were thawed and resuspended in approximately
750 µl of 0.1 M phosphate buffer, pH 7.2 (PBS), and then adjusted for
consistent protein concentrations using the Bio-Rad protein assay
(Bio-Rad Laboratories, Hercules, Calif.). Equal membrane protein
aliquots (approximately 7 to 14 mg/ml) were reacted with bio-Amox at
concentrations of 4, 0.4, and 0.04 µg/ml for 30 min at room
temperature. Membrane fractions were then prepared as described
previously (7), adjusted for consistent protein
concentrations, and separated using sodium dodecyl sulfate-10%
polyacrylamide gel electrophoresis (SDS-10% PAGE). For whole-cell
labeling studies, 2 ml of 48-h cultures of Amoxs and
Amoxr strains were adjusted for consistent optical
densities at 600 nm (~0.25) and labeled with bio-Amox at
concentrations of 4, 0.4, and 0.04 µg/ml for 30 min at room
temperature. The bacteria were then washed twice in PBS, resuspended in
12 µl of distilled water, and then disrupted in Laemmli sample
buffer, boiled, and separated by SDS-10% PAGE. After electrophoresis,
proteins were transferred to nitrocellulose and prepared for detection
by chemiluminescence as described previously (7). Membranes
were exposed to ECL Hyperfilm (Amersham) for 10 to 60 s until
banding patterns appeared. Resulting banding patterns were read for
absorbance intensities using densitometric tracings with an Ultroscan
XL laser densitometer (LKB Products, Bromma, Sweden).
Affinity of PBP 1 for mezlocillin and penicillin
G.
Log-phase H. pylori membrane fractions from the
Amoxs and Amoxr strains were prepared as
described above and incubated with either mezlocillin
(Mezlin; Miles, West Haven, Conn.) or penicillin G (penicillin G
potassium; Marsham, Cherry Hill, N.J.) at 1, 10, and 100 times the
respective MIC for the Amoxs strain for 30 min at room
temperature prior to labeling with bio-Amox. The resulting PBP banding
pattern intensity was determined as described above.
Uptake studies using [14C]penicillin G.
Log-phase Amoxs and Amoxr cultures were
concentrated to 3 × 109 to 5 × 109
bacteria/ml and then were incubated with 6.7 µg of
[14C]penicillin G (1 µCi/ml; Amersham) per ml for
1 h. One-milliliter aliquots were taken at 5, 10, 30, and 60 min,
centrifuged, and washed four times in PBS. The resulting pellets and
washes were then diluted in scintillation fluid (CytoScint;
FisherBiotech) and analyzed for radioactivity in a Beckman LS 6500 scintillation counter (Beckman Instruments, Palo Alto, Calif.).
Carbonyl cyanide m-chlorophenylhydrazone (CCCP; Sigma) was
prepared and stored per the manufacturer's instructions.
Amoxr cultures were prepared as described above and
incubated with a final concentration of 40 µM CCCP according to the
method of Bina et al. (3) 15 min prior to treatment with
[14C]penicillin G and then analyzed as described above.
 |
RESULTS |
Development and characterization of amoxicillin resistance.
An
Amoxr strain of H. pylori ATCC 43579 was
obtained by subculturing an Amoxs parental strain (MIC = 0.03 to 0.06 µg/ml) in increasingly higher concentrations of
amoxicillin. As shown in Table 1, after
39 passes (a period of ~4 months), an isolate for which the MIC was 4 to 8 µg/ml was obtained. There were several noticeable plateaus during this subculturing period, particularly at 0.5 and 2 to 4 µg/ml, where the MICs remained constant for up to a month before increasing to the next MIC. However, after reaching 4 to 8 µg/ml, the
MIC remained unchanged even after many repeat subcultures in higher
concentrations of amoxicillin, and this isolate, designated Amoxr, was stored frozen at
80°C and used for all
subsequent experiments described below.
This level of amoxicillin resistance in Amoxr proved to be
stable for at least 6 months at
80°C. Resistance was also found to
be stable even after subculturing of the Amoxr strain in
media without antibiotic for at least five consecutive passes. The MICs
and MBCs of eight
-lactam antibiotics for the Amoxs and
Amoxr strains are shown in Table
2. The Amoxr strain
demonstrated cross-resistance to each of the
-lactams examined, with
MICs increasing between 4- and 133-fold. Most noticeably, the MICs for
the Amoxr strain increased significantly for ampicillin and
penicillin G (both 133-fold), cefuroxime (67-fold), and
mezlocillin (32-fold).
-Lactamase production.
-Lactamase activity was not
detected in either the Amoxr or Amoxs strains.
PBP profiles.
Isolated membrane fractions from both the
Amoxs and Amoxr strains were prepared and
incubated with bio-Amox as described in the Materials and Methods
section, and the PBP profiles for each strain were compared. Results of
a representative experiment are shown in Fig.
1, and the data from repeat experiments
analyzed quantitatively are presented in Fig.
2. In the range of the MIC for the
Amoxs strain (0.04 µg/ml), the banding intensity of PBP 1 in the Amoxr strain was decreased by >95% from that of
the Amoxs parental strain and by >50% at 10 times the MIC
(0.4 µg/ml). However, at 4 µg/ml (the MIC for the resistant
strain), labeling of PBP 1 in both strains was identical. Labeling of
PBP 2 and PBP 3 with bio-Amox in the Amoxr strain was
comparable to that in the Amoxs strain at each of the
bio-Amox concentrations tested.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 1.
Membranes from Amoxs (S) and
Amoxr (R) H. pylori strains were incubated with
bio-Amox at 4, 0.4, and 0.04 µg/ml, separated by SDS-PAGE, and
visualized on Western blots by chemiluminescence; results of a
representative experiment are shown here. Molecular mass markers (M)
are on the left.
|
|

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 2.
Membranes from Amoxs and Amoxr
strains of H. pylori were incubated with bio-Amox at 4, 0.4, and 0.04 µg/ml, separated by SDS-PAGE, and visualized on Western
blots by chemiluminescence. These blots were then quantitatively
analyzed by laser densitometry. Lightface bars, Amoxs
strain; boldface bars, Amoxr strain; open bars, 4 µg of
bio-Amox per ml; dotted bars, 0.4 µg of bio-Amox per ml; hatched
bars, 0.04 µg of bio-Amox per ml. Abs., absorbance. Data bars
represent the means plus standard errors of the means based on three
separate experiments.
|
|
Additional studies were done using bio-Amox labeling of log-phase
whole-cell cultures of the Amoxs and Amoxr
strains, and the PBP profiles from these experiments are shown in Fig.
3. In these experiments, decreased
labeling of both PBP 1 and PBP 2 was detected at all three bio-Amox
concentrations tested. The banding intensity of PBP 1 was decreased by
>90% using bio-Amox at the MIC for the Amoxs strain (0.04 µg/ml) and by >50% at 10 and 100 times the MIC. In addition, the
banding intensity of PBP 2 was decreased by >75% using bio-Amox
at the MIC and by >33 and 50% at 10 and 100 times the MIC,
respectively. A decrease in banding intensity for PBP 3 of >75% in
the Amoxr strain was detected only with the smallest amount
of bio-Amox tested.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 3.
Intact log-phase cultures of H. pylori cells
were incubated with bio-Amox at 4, 0.4, and 0.04 µg/ml, separated by
SDS-PAGE, visualized on Western blots by chemiluminescence, and then
quantitatively analyzed by laser densitometry. Lightface bars,
Amoxs strain; boldface bars, Amoxr strain; open
bars, 4 µg of bio-Amox per ml; dotted bars, 0.4 µg of bio-Amox per
ml; hatched bars, 0.04 µg of bio-Amox per ml. Abs., absorbance. Data
bars represent the means plus standard errors of the means based on
three separate experiments.
|
|
Affinity of PBP 1 for mezlocillin and penicillin
G.
In order to compare the binding affinity of PBP 1 for other
-lactam antibiotics, competitive binding experiments were conducted using 4 µg of bio-Amox per ml, a concentration found previously to
just saturate PBP 1 of both strains (data not shown) and above our
reported 50% inhibitory concentration (IC50) of
amoxicillin for PBP 1 in the Amoxs strain (3 µg/ml)
(7). In these studies, isolated membranes from the
Amoxs and Amoxr strains were preincubated with
various concentrations of mezlocillin or penicillin G prior
to addition of bio-Amox. Consequently, the decrease in bio-Amox
labeling relative to that in membrane fractions incubated without
competing antibiotic represents the ability of each antibiotic to
compete with bio-Amox for the binding of PBP 1.
A marked decrease in the affinity of PBP 1 from the Amoxr
strain for mezlocillin was demonstrated using 10 times the
mezlocillin MIC for the Amoxs strain, with a
modest decrease seen at the MIC (Table
3). At 100 times the MIC, labeling of PBP
1 by bio-Amox was nearly identical in both strains. In contrast, there
was only a slight drop in affinity of PBP 1 in the Amoxr
strain for penicillin G at 10 times the MIC, with no significant difference in bio-Amox labeling of PBP 1 at 1 or 100 times the MIC for
the two strains.
Uptake of [14C]penicillin G by the
Amoxs and Amoxr strains.
Comparison
of the quantitative uptake of 14C-labeled penicillin G by
the Amoxs and Amoxr strains demonstrated that
the Amoxr strain accumulated >40% less
[14C]penicillin G than equal numbers of
Amoxs bacteria at each time point examined (Fig.
4). When these studies were repeated
using the proton translocator CCCP (which would affect the proton
motive force), the same level of uptake of
[14C]penicillin G by the Amoxr strain
was observed (Fig. 5).

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 4.
Log-phase H. pylori 43579 Amoxs
and Amoxr cultures were incubated with
[14C]penicillin G and 1-ml aliquots were taken at 5, 10, 30, and 60 min, centrifuged, and washed; the resulting pellets and
washes were then analyzed for radioactivity in a scintillation counter.
Squares, Amoxs strain; triangles, Amoxr strain.
Data bars represent the means ± standard errors of the means
based on five separate experiments.
|
|

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 5.
Log-phase H. pylori 43579 Amoxr
cultures were preincubated with either PBS or CCCP for 15 min prior to
incubation with [14C]penicillin G for 1 h.
One-milliliter aliquots were taken at 5, 10, 30, and 60 min,
centrifuged, and washed; the resulting pellets and washes were then
analyzed for radioactivity in a scintillation counter. Triangles,
Amoxr strain without CCCP treatment; circles,
Amoxr strain with CCCP treatment. Data bars represent the
means ± standard errors of the means based on three separate
experiments.
|
|
 |
DISCUSSION |
Previous studies (7) have shown that H. pylori strain ATCC 43579 is very susceptible to amoxicillin, one
of the major antibiotics used in treatment of H. pylori
infections. In this study we isolated an Amoxr strain of
H. pylori by subculturing the Amoxs parental
strain in increasingly higher concentrations of amoxicillin over 4 months, resulting in a final MIC of 4 to 8 µg/ml, 133-fold higher
than the MIC for the original Amoxs strain.
Cross-resistance to other
-lactams was also noted, with MICs
increasing between 4- and 133-fold. Amoxicillin resistance in
-lactamase-negative H. pylori clinical isolates has also
been associated with cross-resistance to other
-lactams
(11).
This amoxicillin resistance proved to be quite stable, both to freezer
storage and to subculture in media without amoxicillin. Stable
amoxicillin resistance has also been described by van Zwet et al.
(38) with an H. pylori strain resistant to 8 µg
of amoxicillin per ml. Han et al. (22) described both stable
and unstable amoxicillin resistance (256 µg/ml) in H. pylori clinical isolates, with the unstable isolates losing
resistance after freezer storage. Selection for amoxicillin
resistance did not appear to adversely affect the metabolic fitness of
the Amoxr strain even after freezer storage, as
differences in growth rates between the Amoxs and
Amoxr freezer stocks were not detected (data not shown).
Amoxicillin resistance in this Amoxr isolate was not found
to be due to the acquisition or expression of a
-lactamase, since
-lactamase activity was not detected in either strain. This was not
too surprising, since there are no
-lactamase homologue genes in
either of the two strains of H. pylori which have been
sequenced (2, 37).
PBP profiles generated by labeling isolated H. pylori
membrane fractions showed significantly decreased bio-Amox labeling of
PBP 1 in the Amoxr strain compared to that of the
Amoxs strain. Previous studies in our laboratory have shown
PBP 1 to be a major target for the binding of
-lactam
antibiotics (7). In contrast, no significant decrease in
bio-Amox labeling of PBP 2 or PBP 3 was observed in the
Amoxr strain in these experiments. From these studies it
would appear that amoxicillin resistance in H. pylori ATCC
43579 is due, at least in part, to an alteration in PBP 1.
The decreased labeling of PBP 1 by bio-Amox in the
Amoxr strain could have been due to either a decreased
number of PBP 1 molecules produced or a decreased affinity of PBP
1 for amoxicillin. To address this, the relative affinity of PBP
1 in the Amoxr and Amoxs strains for two other
-lactam antibiotics was investigated. For these studies we selected
mezlocillin, which has a low IC50 for PBP 1 in
the Amoxs strain (0.125 µg/ml, the same as the MIC for
the Amoxs strain), representing a strong
affinity of PBP 1 for this
-lactam, and penicillin G, which
has a relatively high IC50 for PBP 1 in the
Amoxs strain (>3 µg/ml, which is >100 times the MIC for
the Amoxs strain), representing a much lower affinity for
this
-lactam (7).
From these experiments, it was found that PBP 1 from the
Amoxr strain had significantly decreased binding affinity
for mezlocillin but had an affinity for binding to
penicillin G similar to that of PBP 1 from the Amoxs
strain. The decrease in mezlocillin's ability to compete
with the bio-Amox label for PBP 1 in the Amoxr strain is
consistent with a change in affinity of this PBP for the antibiotic.
However, the fact that penicillin G competed comparably in the
Amoxs and Amoxr strains indicates that the same
number of PBP 1 proteins are produced in these two strains but that
their affinity for amoxicillin and mezlocillin has been
reduced in the Amoxr strain, rendering this strain more
resistant to the effects of amoxicillin.
When the PBP profiles of bio-Amox labeling in the Amoxs and
Amoxr strains were examined using whole-cell labeling
studies, decreased labeling of all three major PBPs was observed in the
Amoxr strain, with significant decreases in PBP 1 and PBP 2 detected at all bio-Amox concentrations tested. Since we had not noted a significant decrease in PBP 2 or PBP 3 labeling using isolated membranes, this suggested the possibility that the bacterial cell membrane of the Amoxr strain was less permeable to
amoxicillin than the Amoxs strain. This was confirmed
by demonstrating that the Amoxr strain accumulated >40%
less [14C]penicillin G than the Amoxs
strain. When the Amoxr strain was pretreated with the
proton translocator CCCP, which would effectively knock out active
transport mechanisms, the level of uptake of
[14C]penicillin G by the Amoxr strain was
unaltered. These studies demonstrated that the decreased accumulation
of [14C]penicillin G by the Amoxr strain is
not due to an active efflux mechanism, a result consistent with
the observation reported by Bina et al. (3) that
active efflux does not play a role in antibiotic resistance in H. pylori. These results suggest that amoxicillin resistance in the
Amoxr strain is due in part to an increased diffusional
barrier to
-lactam antibiotics in the Amoxr strain
compared to the Amoxs strain. The uptake change could be
due to an alteration in an outer membrane protein serving as a
porin. One candidate for this would be HopE, a nonspecific porin
protein in H. pylori, with a large channel through which
antibiotics are likely to be able to cross the outer membrane
(8).
We were surprised to identify two different antibiotic resistance
mechanisms in the Amoxr isolate. However, it seems unlikely
that the full increase in the MIC for the Amoxr strain
(4 to 8 µg/ml) could be completely explained by the decrease in affinity of PBP 1, because when the highest level of bio-Amox was used (4 µg/ml), there was equivalent binding of bio-Amox to PBP 1 in the Amoxs and Amoxr strain using isolated
membranes. When whole cells were labeled by the same method, not only
did PBP 1 show a decrease in bio-Amox labeling at 4 µg/ml, but
there was also a decrease in PBP 2 labeling in the
Amoxr strain. These results pointed to a second
mechanism of
-lactam resistance, namely, an increased
permeability barrier in the Amoxr strain. This is also
supported by the increased resistance of the Amoxr strain
to penicillin G without a significant change in affinity of PBP 1 for
this antibiotic. Interestingly, there were several plateaus noted
during the subculturing experiments which led to the final selection of
this Amoxr strain. Thus, one mechanism of resistance may
have been selected for prior to a second mechanism of resistance
appearing. At what MIC each mechanism was selected for is unknown;
future studies are planned to address this question.
The only amoxicillin resistance mechanism of H. pylori
previously described was one reported in a study by Dore et al.
(10), in which amoxicillin resistance was associated with a
loss of PBP D (molecular mass of 30 to 32 kDa) in amoxicillin-resistant clinical isolates. The amoxicillin resistance was associated with an
amoxicillin tolerance MBC/MIC ratio of
32. In contrast, the amoxicillin resistance characterized in this study appears not only to
be stable but also to have MBC/MIC ratios in the range of 1 to 4, in
contrast to that observed in strains displaying amoxicillin tolerance
as described by Dore et al. (12).
In conclusion, we have identified several mechanisms of
amoxicillin resistance in H. pylori ATCC 43579 related to
a decreased affinity of PBP 1 for amoxicillin as well as a
decrease in uptake of
-lactam antibiotics. Future studies are
planned to characterize the change in PBP 1 as well as the mechanism
conferring a decreased uptake of
-lactam antibiotics in this
Amoxr strain of H. pylori. It will be
interesting to determine whether these mechanisms of amoxicillin
resistance are present in some of the emerging clinical isolates of
H. pylori. A better understanding of antibiotic resistance
mechanisms in H. pylori is important in guiding
therapeutic choices for treatment and in suggesting alternative
strategies at combating these infections.
 |
ACKNOWLEDGMENTS |
We thank Sacred Heart Medical Center of Spokane, Wash., for
supplying the antibiotics at cost and R. Hatch for photographic assistance.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Division of
Biomedical Sciences, University of California, Riverside, Riverside, CA 92521. Phone: (909) 787-4569. Fax: (909) 787-5504. E-mail:
neal.schiller{at}ucr.edu.
 |
REFERENCES |
| 1.
|
Alarcon, T.,
D. Domingo, and M. Lopez-Brea.
1999.
Antibiotic resistance problems with Helicobacter pylori.
Int. J. Antimicrob. Agents
12:19-26[CrossRef][Medline].
|
| 2.
|
Alm, R. A.,
L. S. Ling,
D. T. Moir,
B. L. King,
E. D. Brown,
P. C. Doig,
D. R. Smith,
B. Noonan,
B. C. Guild,
B. L. deJonge,
G. Carmel,
P. J. Tummino,
A. Caruso,
M. Uria-Nickelsen,
D. M. Mills,
C. Ives,
R. Gibson,
D. Merberg,
S. D. Mills,
Q. Jiang,
D. E. Taylor,
G. F. Vovis, and T. J. Trust.
1999.
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori.
Nature
14:176-180.
|
| 3.
|
Bina, J. E.,
R. A. Alm,
M. Uria-Nickelsen,
S. R. Thomas,
T. J. Trust, and R. E. W. Hancock.
2000.
Helicobacter pylori uptake and efflux: basis for intrinsic susceptibility to antibiotics in vitro.
Antimicrob. Agents Chemother.
44:248-254[Abstract/Free Full Text].
|
| 4.
|
Blumberg, P. M., and J. L. Strominger.
1974.
Interaction of penicillin with the bacterial cell: penicillin-binding proteins and penicillin-sensitive enzymes.
Bacteriol. Rev.
38:291-335[Free Full Text].
|
| 5.
|
Dargis, M., and F. Malouin.
1994.
Use of biotinylated -lactams and chemiluminescence for study and purification of penicillin-binding proteins in bacteria.
Antimicrob. Agents Chemother.
38:973-980[Abstract/Free Full Text].
|
| 6.
|
Debets-Ossenkopp, Y. J.,
M. Sparrius,
J. G. Kusters,
J. J. Kolkman, and C. M. J. E. Vandenbroucke-Grauls.
1996.
Mechanism of clarithromycin resistance in clinical isolates of Helicobacter pylori.
FEMS Microbiol. Lett.
142:37-42[CrossRef][Medline].
|
| 7.
|
DeLoney, C. R., and N. L. Schiller.
1999.
Competition of various -lactam antibiotics for the major penicillin-binding proteins of Helicobacter pylori: antibacterial activity and effects on bacterial morphology.
Antimicrob. Agents Chemother.
43:2702-2709[Abstract/Free Full Text].
|
| 8.
|
Doig, P.,
M. M. Exner,
R. E. W. Hancock, and T. J. Trust.
1995.
Isolation and characterization of a conserved porin protein from Helicobacter pylori.
J. Bacteriol.
177:5447-5452[Abstract/Free Full Text].
|
| 9.
|
Domingo, D.,
T. Alarcon,
J. C. Sanz,
I. Sanchez, and M. Lopez-Brea.
1998.
High frequency of mutations at position 2144 of the 23S rRNA gene in clarithromycin-resistant Helicobacter pylori strains isolated in Spain.
J. Antimicrob. Chemother.
41:573-574[Free Full Text].
|
| 10.
|
Dore, M. P.,
D. Y. Graham, and A. R. Sepulveda.
1999.
Different penicillin-binding protein profiles in amoxicillin-resistant Helicobacter pylori.
Helicobacter
4:154-161[CrossRef][Medline].
|
| 11.
|
Dore, M. P.,
D. Y. Graham,
A. R. Sepulveda,
G. Realdi, and M. S. Osato.
1999.
Sensitivity of amoxicillin-resistant Helicobacter pylori to other penicillins.
Antimicrob. Agents Chemother.
43:1803-1804[Abstract/Free Full Text].
|
| 12.
|
Dore, M. P.,
M. S. Osato,
G. Realdi,
I. Mura,
D. Y. Graham, and A.R. Sepulveda.
1999.
Amoxycillin tolerance in Helicobacter pylori.
J. Antimicrob. Chemother.
43:47-54[Abstract/Free Full Text].
|
| 13.
|
Dore, M. P.,
A. Piana,
M. Carta,
A. Atzei,
B. M. Are,
I. Mura,
G. Massarelli,
A. Maida,
A. R. Sepulveda,
D. Y. Graham, and G. Realdi.
1998.
Amoxycillin resistance is one reason for failure of amoxycillin-omeprazole treatment of Helicobacter pylori infection.
Aliment. Pharmacol. Ther.
12:635-639[CrossRef][Medline].
|
| 14.
|
Dunn, B. E.,
H. Cohen, and M. J. Blaser.
1997.
Helicobacter pylori.
Clin. Microbiol. Rev.
10:720-741[Abstract].
|
| 15.
|
Georgopapadakou, N. H.
1993.
Penicillin-binding proteins and bacterial resistance to -lactams.
Antimicrob. Agents Chemother.
37:2045-2053[Free Full Text].
|
| 16.
|
Ghuysen, J. M.
1997.
Penicillin-binding proteins. Wall peptidoglycan assembly and resistance to penicillin: facts, doubts and hopes.
Int. J. Antimicrob. Agents
8:45-60.
|
| 17.
|
Gibaldi, M.
1995.
Helicobacter pylori and gastrointestinal disease.
J. Clin. Pharmacol.
35:647-654[Abstract]
|
| 18.
|
Goodwin, C. S.
1997.
Antimicrobial treatment of Helicobacter pylori infection.
Clin. Infect. Dis.
25:1023-1026[Medline].
|
| 19.
|
Graham, D. Y.
1998.
Antibiotic resistance in Helicobacter pylori: implications for therapy.
Gastroenterology
115:1272-1277[CrossRef][Medline].
|
| 20.
|
Grebe, T., and R. Hakenbeck.
1996.
Penicillin-binding proteins 2b and 2x of Streptococcus pneumoniae are primary resistance determinants for different classes of -lactam antibiotics.
Antimicrob. Agents Chemother.
40:829-834[Abstract].
|
| 21.
|
Hakenbeck, R.
1995.
Target-mediated resistance to -lactam antibiotics.
Biochem. Pharmacol.
50:1121-1127[CrossRef][Medline].
|
| 22.
|
Han, S.-R.,
S. Bhakdi,
M. J. Maeurer,
T. Schneider, and S. Gehring.
1999.
Stable and unstable amoxicillin resistance in Helicobacter pylori: should antibiotic resistance testing be perfomed prior to eradication therapy?
J. Clin. Microbiol.
37:2740-2741[Free Full Text].
|
| 23.
|
Harris, A. G.,
S. L. Hazell, and A. G. Netting.
2000.
Use of digoxigenin-labelled ampicillin in the identification of penicillin-binding proteins in Helicobacter pylori.
J. Antimicrob. Chemother.
45:591-598[Abstract/Free Full Text].
|
| 24.
|
Heep, M.,
D. Beck,
E. Bayerdörffer, and N. Lehn.
1999.
Rifampin and rifabutin resistance mechanism in Helicobacter pylori.
Antimicrob. Agents Chemother.
43:1497-1499[Abstract/Free Full Text].
|
| 25.
|
Ikeda, F.,
Y. Yokota,
A. Ikemoto,
N. Teratani,
K. Shimomura, and H. Kanno.
1995.
Interaction of beta-lactam antibiotics with the penicillin-binding proteins of penicillin-resistant Streptococcus pneumoniae.
Chemotherapy
41:159-164[Medline].
|
| 26.
|
Ikeda, F.,
Y. Yokota,
Y. Mine, and M. Tatsuta.
1990.
Activity of cefixime against Helicobacter pylori and affinities for the penicillin-binding proteins.
Antimicrob. Agents Chemother.
34:2426-2428[Abstract/Free Full Text].
|
| 27.
|
Iovene, M. R.,
M. Romano,
A. P. Pilloni,
B. Giordano,
F. Montella,
S. Caliendo, and M. A. Tufano.
1999.
Prevalence of antimicrobial resistance in eighty clinical isolates of Helicobacter pylori.
Chemotherapy
45:8-14[CrossRef][Medline].
|
| 28.
|
Jacoby, G. A., and G. L. Archer.
1991.
New mechanisms of bacterial resistance to antimicrobial agents.
N. Engl. J. Med.
324:601-612[Medline].
|
| 29.
|
Krishnamurthy, P.,
M. H. Parlow,
J. Schneider,
S. Burroughs,
C. Wickland,
N. B. Vakil,
B. E. Dunn, and S. H. Phadnis.
1999.
Identification of a novel penicillin-binding protein from Helicobacter pylori.
J. Bacteriol.
181:5107-5110[Abstract/Free Full Text].
|
| 30.
|
Livermore, D. M.
1995.
-Lactamases in laboratory and clinical resistance.
Clin. Microbiol. Rev.
8:557-584[Abstract].
|
| 31.
|
Malouin, F., and L. E. Bryan.
1986.
Modification of penicillin-binding proteins as mechanisms of -lactam resistance.
Antimicrob. Agents Chemother.
30:1-5[Free Full Text].
|
| 32.
|
McColl, K. E. L.
1999.
Helicobacter pylori 1988-1998.
Eur. J. Gastroenterol. Hepatol.
11:13-16[Medline].
|
| 33.
|
Neuwirth, C.,
E. Siebor,
J.-M. Duez,
A. Pechinot, and A. Kazmierczak.
1995.
Imipenem resistance in clinical isolates of Proteus mirabilis associated with alterations in penicillin-binding proteins.
J. Antimicrob. Chemother.
36:335-342[Abstract/Free Full Text].
|
| 34.
|
Nikaido, H.
1996.
Multidrug efflux pumps of gram-negative bacteria.
J. Bacteriol.
178:5853-5859[Free Full Text].
|
| 35.
|
Parr, T. R., Jr., and L. E. Bryan.
1984.
Mechanism of resistance of an ampicillin-resistant, -lactamase-negative clinical isolate of Haemophilus influenzae type b to -lactam antibiotics.
Antimicrob. Agents Chemother.
25:747-753[Abstract/Free Full Text].
|
| 36.
|
Sörberg, M.,
H. Hanberger,
M. Nilsson,
A. Björkman, and L.E. Nilsson.
1998.
Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori.
Antimicrob. Agents Chemother.
42:1222-1228[Abstract/Free Full Text].
|
| 37.
|
Tomb, J. F.,
O. White,
A. R. Kerlavage,
R. A. Clayton,
G. G. Sutton,
R. D. Fleischmann,
K. A. Ketchum,
H. P. Klenk,
S. Gill,
B. A. Dougherty,
K. Nelson,
J. Quackenbush,
L. Zhou,
E. F. Kirkness,
S. Peterson,
B. Loftus,
D. Richardson,
R. Dodson,
H. G. Khalak,
A. Glodek,
K. McKenney,
L. M. Fitzgerald,
N. Lee,
M. D. Adams, and J. C. Venter.
1997.
The complete genome sequence of the gastric pathogen Helicobacter pylori.
Nature
388:539-547[CrossRef][Medline].
|
| 38.
|
van Zwet, A. A.,
C. M. J. E. Vandenbrouke-Grauls,
J. C. Thijs,
E. J. van der Wouden,
M. M. Gerrits, and J. G. Kusters.
1998.
Stable amoxicillin resistance in Helicobacter pylori.
Lancet
352:1595[Medline].
|
Antimicrobial Agents and Chemotherapy, December 2000, p. 3368-3373, Vol. 44, No. 12
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Megraud, F., Lehours, P.
(2007). Helicobacter pylori Detection and Antimicrobial Susceptibility Testing. Clin. Microbiol. Rev.
20: 280-322
[Abstract]
[Full Text]
-
Co, E.-M. A., Schiller, N. L.
(2006). Resistance Mechanisms in an In Vitro-Selected Amoxicillin-Resistant Strain of Helicobacter pylori. Antimicrob. Agents Chemother.
50: 4174-4176
[Abstract]
[Full Text]
-
Boyanova, L., Nikolov, R., Lazarova, E., Gergova, G., Katsarov, N., Kamburov, V., Spassova, Z., Derejian, S., Jelev, C., Mitov, I., Krastev, Z.
(2006). Antibacterial resistance in Helicobacter pylori strains isolated from Bulgarian children and adult patients over 9 years. J Med Microbiol
55: 65-68
[Abstract]
[Full Text]
-
Nahar, S., Mukhopadhyay, A. K., Khan, R., Ahmad, M. M., Datta, S., Chattopadhyay, S., Dhar, S. C., Sarker, S. A., Engstrand, L., Berg, D. E., Nair, G. B., Rahman, M.
(2004). Antimicrobial Susceptibility of Helicobacter pylori Strains Isolated in Bangladesh. J. Clin. Microbiol.
42: 4856-4858
[Abstract]
[Full Text]
-
Megraud, F
(2004). H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut
53: 1374-1384
[Full Text]
-
Shin, J.-H., Roe, I.-H., Kim, H.-G.
(2004). Production of anti-Helicobacter pylori urease-specific immunoglobulin in egg yolk using an antigenic epitope of H. pylori urease. J Med Microbiol
53: 31-34
[Abstract]
[Full Text]
-
Kwon, D. H., Dore, M. P., Kim, J. J., Kato, M., Lee, M., Wu, J. Y., Graham, D. Y.
(2003). High-Level {beta}-Lactam Resistance Associated with Acquired Multidrug Resistance in Helicobacter pylori. Antimicrob. Agents Chemother.
47: 2169-2178
[Abstract]
[Full Text]
-
Okamoto, T., Yoshiyama, H., Nakazawa, T., Park, I.-D., Chang, M.-W., Yanai, H., Okita, K., Shirai, M.
(2002). A change in PBP1 is involved in amoxicillin resistance of clinical isolates of Helicobacter pylori. J Antimicrob Chemother
50: 849-856
[Abstract]
[Full Text]
-
Shin, J.-H., Yang, M., Nam, S. W., Kim, J. T., Myung, N. H., Bang, W.-G., Roe, I. H.
(2002). Use of Egg Yolk-Derived Immunoglobulin as an Alternative to Antibiotic Treatment for Control of Helicobacter pylori Infection. CVI
9: 1061-1066
[Abstract]
[Full Text]
-
Gerrits, M. M., Schuijffel, D., van Zwet, A. A., Kuipers, E. J., Vandenbroucke-Grauls, C. M. J. E., Kusters, J. G.
(2002). Alterations in Penicillin-Binding Protein 1A Confer Resistance to {beta}-Lactam Antibiotics in Helicobacter pylori. Antimicrob. Agents Chemother.
46: 2229-2233
[Abstract]
[Full Text]
-
Torres, J., Camorlinga-Ponce, M., Perez-Perez, G., Madrazo-De la Garza, A., Dehesa, M., Gonzalez-Valencia, G., Munoz, O.
(2001). Increasing Multidrug Resistance in Helicobacter pylori Strains Isolated from Children and Adults in Mexico. J. Clin. Microbiol.
39: 2677-2680
[Abstract]
[Full Text]